ONCOSTATIN M INDUCES VEGF IN HUMAN BREAST CARCINOMA CELLS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 抑癌素M诱导人乳腺癌细胞血管内皮生长因子的体内外血管生成 肿瘤素M是一种多效性细胞因子，由多种细胞类型产生，包括中性粒细胞和肿瘤相关巨噬细胞。OSM抑制乳腺癌细胞的增殖，因此正在研究其在癌症治疗中的潜在用途。我们实验室的初步结果表明，OSM可能促进肿瘤细胞中的促血管生成因子。其他研究表明，OSM在肿瘤相关的中性粒细胞和乳腺癌上皮细胞中表达，但在正常乳腺癌组织中不表达。我们的数据表明，OSM刺激乳腺癌细胞产生血管生成相关的基质金属蛋白酶(MMPs)和血管内皮生长因子-A(VEGF)，这是一种非常有效的血管生成因子。我们的目标是了解血管内皮生长因子诱导的意义，以正确评估OSM作为临床癌症治疗的潜力。 我们推测，经OSM处理的乳腺癌细胞产生的血管内皮生长因子将在体外和体内刺激血管生成。我们的具体目标包括：1)确定诱导血管内皮生长因子的OSM受体和信号通路；2)证明经OSM处理的乳腺癌细胞产生的血管内皮生长因子将在培养的血管内皮细胞中诱导血管生成表型；3)研究OSM诱导的血管生成因子在体内刺激血管生成和促进乳腺癌进展的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Oncostatin M induces VEGF in human breast carcinoma cells: stimulation of angiogenesis in vitro and in vivo. Oncostatin M is a pleiotropic cytokine produced by many cell types, including neutrophils and tumor-associated macrophages. OSM inhibits proliferation of breast cancer cells, and for this reason is being examined for its potential use in cancer treatment. Preliminary results from our lab show that OSM may promote pro-angiogenic factors in tumor cells. Additional studies show that OSM is expressed by tumor-associated neutrophils and breast cancer epithelial cells, but not by normal breast cancer tissue. Our data indicate that OSM stimulates breast cancer cells to produce angiogenesis-related matrix metalloproteinases (MMPs) and vascular endothelial growth factor-A (VEGF), which is an extremely potent angiogenic factor. Our goal is to understand the implications of VEGF induction to correctly evaluate the potential of OSM as a clinical cancer treatment. We hypothesize that VEGF produced by OSM-treated breast cancer cells will stimulate angiogenesis in vitro and in vivo. Our specific aims include: 1) To determine the OSM receptor and signaling pathway utilized to induce VEGF; 2) To demonstrate that VEGF produced by OSM-treated breast cancer cells will induce an angiogenic phenotype in cultured endothelial cells; and 3) To investigate the ability of OSM-induced VEGF to stimulate angiogenesis and promote the progression of breast carcinoma in vivo.